ATCC to Showcase Physiologically Relevant Cell Models for Cancer Research at American Association for Cancer Research Annual Meeting
Subject matter experts will share the importance of isogenic cell lines and genomic reference standards in cancer research
MANASSAS, VA, (April 12, 2018) — ATCC, the premier global biological materials resource and standards organization, and leading, developer and supplier of authenticated cells and advanced cell models, will showcase its expanded portfolio of cancer research tools at the upcoming annual meeting of the American Association for Cancer Research (AACR). This meeting will take place April 14-18 at McCormick Place in Chicago, IL.
ATCC will feature uniquely physiologically relevant isogenic cell lines that contain genetic alterations introduced via CRISPR/Cas9 genome-editing technology. These disease-relevant alterations are specifically designed to enable cancer researchers to investigate key mutations related to cancer genesis and progression for potential use for identifying personalized treatment regimens.
“To support the development of new cancer drugs, ATCC scientists continue to develop in vitro cancer models that meet today’s research challenges of being more predictive and more versatile, enabling culture in both 2-D and 3-D formats,” said Dr. Raymond Cypess, ATCC Chairman and CEO. “The AACR annual meeting represents a great opportunity for ATCC to collaborate with the cancer research community and explore innovations in cancer research.”
In addition to the CRISPR/Cas9-edited cell lines, ATCC will display well-characterized primary cells, cancer cell panels, and authenticated cell models—such as hTERT-immortalized primary cells and other genetically modified cells — meeting a wide variety of cancer research needs.
On April 14th, Dr. Maryellen de Mars, Vice President, Standards Resource Center, ATCC will participate in the Cancer Genomic Reference Samples – Sequencing Consortium Results and Beyond session during one of several education workshops. The consortium will provide a progress update on the FDA-led Sequencing Quality Control Phase II (SEQC2). Dr. de Mars will discuss the pre-analytical aspects of the ATCC cell lines used for this analysis. The Consortium is comprised of 60+ institutions and 160+ scientists that have joined to characterize and compare both a breast cancer and a normal cell line for the purpose of defining high confidence mutation cells. These reference cells will serve as controls for somatic mutation-based diagnostic tests.
In addition to its booth presence in the AACR exhibit hall, ATCC subject matter experts will present a number of poster demonstrations including a unique in vitro model for cancer metastasis research.
ATCC is a leader in biological materials management, providing the worldwide scientific community and U.S. government with research and development, standardized products, and services in support of global health issues. With a history of innovation spanning more than 90 years, ATCC offers the world’s largest and most diverse collection of human and animal cell lines, microorganisms, biological products, and standards. ATCC is a non-profit organization with headquarters in Manassas, VA, and an R&D and services center in Gaithersburg, MD. For more information about ATCC, visit us at www.atcc.org.
CRISPR Isogenic Cell Models Video
ATCC R&D Capability